Dipal Doshi, Entrada Therapeutics CEO

En­tra­da hit with clin­i­cal hold on Duchenne drug

When En­tra­da Ther­a­peu­tics un­veiled its shiny new al­liance with Ver­tex days ago sur­round­ing my­oton­ic dy­s­tro­phy Type I, CEO Di­pal Doshi took the op­por­tu­ni­ty to spot­light …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.